Testing a score-guided blood-thinner duration after coronary stenting
Compares a score-based plan for blood thinner length with usual care in adults having stents.
Plain-language title generated from the registry record
Registry title: Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
Key facts
- Where
- Roma, ItalySee the site
Where in Italy
- UOC Cardiologia San Giovanni Addolorata HospitalRoma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT05732701
- Record updated
- 3 November 2026
- Original description
The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation. The TAILOR-DAPT trial aims to investigate the benefits of a score-based decision-making algorithm to guide DAPT duration compared to a standard-of-care DAPT duration without the use of risk scores in patients undergoing PCI.Read full original descriptionShow less
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
The use of aspirin combined with a P2Y12 inhibitor (dual antiplatelet therapy, DAPT) represents the standard of care for patients undergoing percutaneous coronary intervention (PCI) with stent implantation. The TAILOR-DAPT trial aims to investigate the benefits of a score-based decision-making algorithm to guide DAPT duration compared to a standard-of-care DAPT duration without the use of risk scores in patients undergoing PCI.
Inclusion: PCI with drug eluting stent (DES) implantation; Age ≥18 years; Ability to sign informed consent before any study-specific procedure.
Exclusion: Treatment for stent thrombosis at qualifying PCI or within 1 year prior to qualifying PCI; Planned surgery within the next 3 months; Participation in a drug trial; Peri-procedural complication which affects DAPT regimen based on the operator's opinion (e.g. untreated flow-limiting angiographic complication, intraprocedural stent thrombosis, persistent vessel occlusion/no-reflow at the end of the procedure, major side-branch occlusion, puncture-site related or other relevant bleeding); Active bleeding requiring medical attention at qualifying PCI; Contraindication or known allergy against aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, and prasugrel); Planned staged PCI (Patients can be enrolled after complete coronary revascularization with no remaining lesions intended for treatment. Patients who have or develop an indication for percutaneous valve intervention can undergo treatment 30 days after full coronary revascularization); Indication for oral anticoagulation; The presence of hemodynamic instability (persistent systolic blood pressure below 90mmHg, continuous infusions of catecholamines, clinical signs of hypoperfusion and/or use of percutaneous left ventricular assist devices); Life expectancy less than 1 year; Women of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile).